loader2
Partner With Us NRI

Company details

2,575.20
2,650.00
2,498.00
4,350.00
6M Return -32.88%
1Y Return -23.00%
Mkt Cap.(Cr) 42,596.37
Volume 5,549
Div Yield 0.00%
OI
-
OI Chg %
-
Volume 5,549

Open Free Demat Account Online with ICICIDIRECT

SWOT

  • swot

  • technicals

  • deals

  • shareholding


EMA SMA

Delivery and volume

Financials

  • Profit and loss statement

  • Balance sheet

  • Quarterly Result

  • Ratio

Sales(Cr.)

Operating Profit(Cr.)

Profit after Tax(Cr.)

Equity

Reserves and Surplus

Debt

Sales

Operating Profit

Profit after tax

PE

Debt/Equity

P BV

INSIDER & INSTITUIONAL ACTIVITY

Equity Capital: 5,903.24 Cr FV: 1.00
Period MF Net Purchase / (sold) FII Net
LAST 1M 18,658.80 -44,480.27
LAST 3M 70,889.04 -85,599.64
LAST 6M 138,573.25 -221,926.67
LAST 12M 230,551.63 -248,467.70

Information

  • About Company
  • Company Info
  • Listing Info
36.09
58%
434.7038
27.99%
20.88%
Description
  • Gland Pharma Ltd is in the Pharmaceuticals sector with the Market Capitalization of worth Rs. 67,419.04 crores, it is incorporated in the year 1978. It has reported the consolidated sales of Rs. 1153.90 crores in June 2021. The company is also listed in the Bombay Stock Exchange (BSE) with the code 543245 and listed in the National Stock Exchange (NSE) with the code GLAND.

    Glen Pharma Ltd was incorporated as Private Company in Hyderabad. The company is primarily involved in the production of injectable drugs. Gland Pharmaceuticals has a global presence in around 60 countries and operates on a business-to-business model in countries like India, the USA, Canada, Australia, and some European countries. Gland Pharma has a total of seven manufacturing units located in different parts of the country. Gland Pharmaceuticals has 1415 product registrations in multiple countries of the world, with 368 product registrations in the USA and 54 registrations in India. The company has all its
    facilities approved by USFDA and has a track record of receiving no warnings. The promoters within the company currently hold 58.14% of the stake in the company.

    The Foreign Institutional Investors (FII) and Domestic Institutional Investors (DII) holds 10.44% and 12.11% of the stake. The balance of 19.32% is by others (retail investors).

    In June 2021, quarterly net sales were Rs. 1,153.90 crores, which has increased by approximately 31% from Rs. 884.21 crores for the April-June 2020 quarter. The quarterly net profit in June 2021 was Rs. 350.68 crores, which has seen a rise by nearly 12% from a net profit of Rs. 313.59 crores in June 2020. In June 2021, operating profit was reported at Rs. 1,137.44 crores, which is also increased by 33% as compared to an operating profit of Rs. 853.76 crores for the quarter ending in June 2020. From Rs. 20.24 in June 2020, the EPS of Gland Pharma Ltd has increased to Rs. 21.41 per share in June 2021. GLAND’s stock closed at Rs. 4131 on 16th August’2021 (NSE) and has returned 86.47% in the last six months and 126.06% in the last year.

Read More

No Data Found

AGM Date (Month) : Aug
Face Value Equity Shares : 1
Market Lot Equity Shares : 1
BSE Code : 543245
NSE Code : GLAND
Book Closure Date (Month) :
BSE Group : A
ISIN : INE068V01023

ICICIdirect Gland Pharma Ltd FAQ

You can buy Gland Pharma Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Gland Pharma Ltd Share.
Company share prices and volatile and keep changing according to the market conditions. As of Jul 04, 2022 04:01 PM the closing price of Gland Pharma Ltd was ₹ 2,592.55.
Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of Jul 04, 2022 04:01 PM, the market cap of Gland Pharma Ltd stood at ₹ 42,596.37.
The latest PE ratio of Gland Pharma Ltd as of Jul 04, 2022 04:01 PM is 36.09
The latest PB ratio of Gland Pharma Ltd as of Jul 04, 2022 04:01 PM is 0.16
The 52-week high of Gland Pharma Ltd is ₹ 4,350.00 while the 52-week low is ₹ 2,498.00 .

Thank you for subscribing to Equity/ Equity Research/MF/FnO Newsletter. You will hear from us shortly.

for your vote

CLOSE